NDA 020815 · Lilly
Evista
Raloxifene Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 27, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Dec 9, 1997
Approved uses
3
Original approval plus efficacy supplements
Registered trials
69
19 Phase 3, 4 recruiting
FAERS reports
14,534
8,238 serious, 560 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE Increased risk of deep vein thrombosis and pulmonary embolism have been reported with EVISTA [see Warnings and Precautions ( 5.1 )] . Women with active or past history of venous thromboembolism should not take EVISTA [see Contraindications ( 4.1 )]. Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke [see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.5 )]. WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE See full prescribing information for complete boxed warning. Increased risk of deep vein thrombosis and pulmonary embolism have been reported with EVISTA ( 5.1 ). Women with active or past history of venous...
What it is approved for
From the label in effect Feb 11, 2026.
EVISTA ® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. ( 1.2 ) Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. ( 1.3 ) Important Limitations: EVISTA is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. ( 1.3 ) 1.1 Treatment and Prevention of Osteoporosis in Postmenopausal Women EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see Clinical Studies ( 14.1 , 14.2 )] . 1.2 Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see Clinical Studies ( 14.3 )] . 1.3 Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women at High Risk of Invasive Breast Cancer EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see Clinical Studies ( 14.4 )] . The effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see Clinical Studies ( 14.4 )] . Twenty-seven percent of the participants received drug for 5 years. The long-term effects and the recommended length of treatment are not known. High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia,...
Mechanism: Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism). The agonistic or antagonistic action of raloxifene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promoters. Raloxifene appears to act as an estrogen agonist in bone. It decreases...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 30, 1999 Supplement 3 · Efficacy · priority review ReviewLabelLetter
- Nov 24, 1998 Supplement 2 · Efficacy Review
- Dec 9, 1997 Original approval · Type 1 - New Molecular Entity · priority review ReviewMedication Guide
1 products under this application
- EVISTA · RALOXIFENE HYDROCHLORIDE 60MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Raloxifene" as an intervention, any sponsor and status, largest first.
- Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal WomenPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00003906 · 19,747 participants · Start May 1999 · Primary completion Dec 2005
Drug: Raloxifene; Tamoxifen · For: Breast Cancer
Sites: Huntsville, Alabama; Mobile, Alabama; Anchorage, Alaska · 516 sites in all
- Raloxifene Use for The HeartPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00190593 · 10,000 participants · Start Jun 1998
Drug: raloxifene; placebo · For: Cardiovascular Diseases; Breast Neoplasms
Sites: Minneapolis, Minnesota
- Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00670319 · 7,705 participants · Start Nov 1994 · Primary completion Sep 1999
Drug: Raloxifene HCL; Raloxifene HCL and 1 more · For: Osteoporosis, Postmenopausal
Sites: San Francisco, California; Ciudad de Buenos Aires, Argentina; Heidelburg, Australia · 25 sites in all
- Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal WomenPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00205777 · 7,609 participants · Start Dec 2001 · Primary completion Sep 2010
Drug: Bazedoxifene Acetate · For: Osteoporosis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 375 sites in all
- Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal WomenPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00675688 · 3,544 participants · Start Apr 2002 · Primary completion Jan 2006
Drug: Bazedoxifene/Conjugate Estrogens (CE); Raloxifene and 1 more · For: Endometrial Hyperplasia; Osteoporosis
- Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal WomenPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00481169 · 1,742 participants · Start Jul 2001 · Primary completion Jul 2004
Drug: Bazedoxifene Acetate (TSE-424) · For: Osteoporosis
- Cognition in the Study of Tamoxifen and RaloxifenePivotal-lookingCompleted
Wake Forest UniversityAcademic, hospital or other
NCT00687102 · 1,498 participants · Start Oct 2001 · Primary completion Mar 2008
Drug: tamoxifen; raloxifene · For: Cognition; Aging
Sites: Phoenix, Arizona; Tucson, Arizona; Camp Pendleton, California · 134 sites in all
- 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00191425 · 810 participants · Start Aug 2002
Drug: Teriparatide; Raloxifene · For: Osteoporosis, Postmenopausal
Sites: Bad Pyrmont, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea777
- fall772
- drug ineffective751
- pain in extremity717
- pain686
- arthralgia637
- dizziness615
- muscle spasms588
- fatigue565
- headache557
- body height decreased532
- back pain470
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,125 |
| 2005 | 990 |
| 2006 | 855 |
| 2007 | 715 |
| 2008 | 758 |
| 2009 | 743 |
| 2010 | 793 |
| 2011 | 621 |
| 2012 | 757 |
| 2013 | 530 |
| 2014 | 554 |
| 2015 | 3,688 |
| 2016 | 471 |
| 2017 | 429 |
| 2018 | 325 |
| 2019 | 291 |
| 2020 | 205 |
| 2021 | 165 |
| 2022 | 145 |
| 2023 | 113 |
| 2024 | 99 |
| 2025 | 96 |
| 2026 | 65 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Evista (Raloxifene HCl)
2024 spending
$925K
Beneficiaries
527
2,355 claims
Per beneficiary
$1,755
$6.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,994,285 |
| 2021 | $1,622,729 |
| 2022 | $1,321,400 |
| 2023 | $1,164,041 |
| 2024 | $924,682 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR, Nicolopoulos K, Stringer D, et al. · Calcif Tissue Int 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S, Simpson E, Hamilton J, et al. · Health Technol Assess 2020 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- One versus 2 years of alendronate following denosumab: the CARD extension.
Tsai JN, Jordan M, Lee H, et al. · Osteoporos Int 2024 · Randomized Controlled Trial, Multicenter Study
- Antiestrogenic properties of raloxifene.
Draper MW, Flowers DE, Neild JA, et al. · Pharmacology 1995 · Clinical Trial, Randomized Controlled Trial
- The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K, Moshi MR, Stringer D, et al. · Arch Osteoporos 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.